Topic: What More We can do on Hepatitis C?
A special issue of Hepatoma Research (Print ISSN：2394-5079; Online ISSN：2454-2520).
Deadline for manuscript submissions: 20 Mar 2018
Share This Special Issue
- Necati Örmeci, MD
- Department of Gastroenterology, Ankara University Medical School, Ankara, Turkey.
Special Issue Introduction:
Hepatitis C virus (HCV) is an enveloped virus with a 9.6 kb single stranded RNA genome. Six HCV genotypes and a large number of subtypes have been identified HCV is an important world-wide health and economic problem through direct and indirect medical cost associated with managing liver disease, decreased work productivity. A hundred eighty million people are infected with HCV in the world. It is thecause of acute hepatitis, chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Besides that, it may results in extra-hepatic manifestations such as mixed cryoglobulinemia, chronic kidney disease, porphyria cutaneatarda, and type 2 diabetes mellitus, rheumatoid-like nondestructive inflammatory arthritis and depression. HCV is associated with the increasing liver related and all causes of mortality.
HCV is one of the important factors (20 % of all causes) for developing the HCC. Almost 700,000 persons died from HCC in a year. HCC is the 6th most common cancer but third common cause of death from the cancer.
Those are the reasons that we made a plan to have a Special Issue about “What More We can do on Hepatitis C?”. It is hoped that this Special Issue will bring novel insights and new solutions to the liver cancer research filed.
This special issue is now open for submission.
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.